RAPT Therapeutics, Inc. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 22nd, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
RAPT THERAPEUTICS, INC. INDEMNITY AGREEMENTIndemnity Agreement • July 22nd, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of between RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
July 20, 2019 Dirk Brockstedt Dear Dirk,Letter Agreement • July 22nd, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • California
This letter agreement (the “Agreement”) sets forth the terms and conditions of your continued employment with RAPT Therapeutics, Inc. (“RAPT” or the “Company”). This Agreement supersedes and replaces all prior written employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not limited to, your initial November 13, 2017 offer letter agreement with the Company.
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between MSD International GmbH and FLX Bio, Inc. Dated: November 1, 2018Clinical Trial Collaboration and Supply Agreement • July 22nd, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of November 1, 2018 (the “Effective Date”), by and between MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern 6, Switzerland (“Merck”), and FLX Bio, Inc., having a place of business at 561 Eccles Ave., South San Francisco, CA 94080 (“FLX”). Merck and FLX are each referred to herein individually as “Party” and collectively as “Parties”.
March 19, 2019 Rekha Hemrajani Dear Rekha:RAPT Therapeutics, Inc. • July 22nd, 2019 • Pharmaceutical preparations • California
This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that FLX Bio, Inc. (the “Company”) is offering to you.
April 30, 2019 Rekha Hemrajani Dear Rekha:RAPT Therapeutics, Inc. • July 22nd, 2019 • Pharmaceutical preparations
This letter is with regard to the separation and consulting agreement (the “Agreement”) between you and FLX Bio, Inc. (the “Company”) dated March 19, 2019. Under Section 4 of the Agreement, you agreed to repay the Company, within 30 days (i.e., by April 18, 2019), a total of $133,566.95 of principal and accrued interest (the “Loan Amount) owed by you to the Company.
